ONKURE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $48.3M | $43.8M | $32.1M | $37.7M | $28.2M | $15.9M |
| SG&A Expense | — | $14.7M | $10.6M | $4.8M | $16.1M | $11.6M | $3.6M |
| Operating Income | — | $-63.0M | $-54.4M | $-36.9M | $-53.8M | $-39.8M | $-19.6M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | $-77.4M | $-52.0M | $-39.8M | $-19.5M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-59.5M | $-52.7M | $-35.3M | $-52.0M | $-39.8M | $-19.5M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-4.40 | $-3.82 | $-31.10 | $-0.53 | $-0.55 | $-0.27 |
| EPS (Diluted) | — | $-4.40 | $-3.82 | $-31.10 | $-0.53 | $-0.55 | $-0.27 |
| Shares Outstanding (Basic) | 13.7M | 13.5M | 13.8M | 122.7M | 98.0M | 72.6M | 73.0M |
| Shares Outstanding (Diluted) | 13.7M | 13.5M | 13.8M | 122.7M | 98.0M | 72.6M | 73.0M |
| Dividends Per Share | — | — | — | — | — | — | — |